Literature DB >> 30084333

Therapeutic Approach for Irritable Bowel Syndrome: Old and New Strategies.

Paolo Usai-Satta1, Massimo Bellini2, Mariantonia Lai3, Francesco Oppia1, Francesco Cabras1.   

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) is the most frequently diagnosed functional gastrointestinal disorder. It is characterised by abdominal pain, bloating and changes in bowel habits that can have a serious impact on the patient's quality of life. Treatment strategies are based on the nature and severity of the symptoms, the degree of functional impairment of the bowel habits, and the presence of psychosocial disorders. The purpose of this review is to update our current knowledge of therapeutic approach of this disorder.
METHOD: A literature search for IBS therapy was carried out using the online databases of Pubmed, Medline and Cochrane.
RESULTS: An ideal treatment begins by explaining this condition and providing reassurance to the patients. There is limited evidence for the efficacy, and tolerability of the therapies currently available for the treatment of IBS. There is also a limited availability of pharmacological agents licensed specifically for the treatment of IBS subtypes, although new agents have been recently proposed to this goal. Furthermore, patients often associate their complaints with the ingestion of foods containing FODMAPs (fermentable oligo-di-monosaccharides, and polyols) and gluten derivates and a personalized diet can be proposed. However, more severe symptoms can be associated with greater levels of psychosocial problems and a psychological approach and antidepressant drugs can be needed.
CONCLUSION: The treatment of IBS remains focused on treating the patient's predominant, or most troublesome, symptoms. New promising treatments have recently become available for the treatment of IBS but long term studies are still needed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Irritable bowel syndrome; constipation; diarrhea; diet; pain; pharmacological agents.

Mesh:

Substances:

Year:  2018        PMID: 30084333     DOI: 10.2174/1574884713666180807143606

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  7 in total

1.  Can Sertraline and Nortriptyline Protect the Neurons in Submucosal and Myenteric Plexuses of Rat's Colon Against Stress?

Authors:  Ali Noorafshan; Majid Yousefi; Leila Hosseini; Saied Karbalay-Doust
Journal:  Dig Dis Sci       Date:  2019-04-01       Impact factor: 3.199

2.  Efficacy and safety of lactulose for the treatment of irritable bowel syndrome.

Authors:  Hong-Bin Chen; Xiao-Ying Su
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

3.  High Rates of Non-Response Across Treatment Attempts in Chronic Irritable Bowel Syndrome: Results From a Follow-Up Study in Tertiary Care.

Authors:  Yuanjun Dong; David Baumeister; Sabrina Berens; Wolfgang Eich; Jonas Tesarz
Journal:  Front Psychiatry       Date:  2019-10-02       Impact factor: 4.157

Review 4.  Effectiveness of vitamin D for irritable bowel syndrome: A protocol for a systematic review of randomized controlled trial.

Authors:  Sheng-Mei Shi; Yan-Li Wen; Hai-Bin Hou; Hai-Xia Liu
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

5.  Irritable Bowel Syndrome and Gluten-Related Disorders.

Authors:  Paolo Usai-Satta; Gabrio Bassotti; Massimo Bellini; Francesco Oppia; Mariantonia Lai; Francesco Cabras
Journal:  Nutrients       Date:  2020-04-17       Impact factor: 5.717

Review 6.  Hydrogen Breath Tests: Are They Really Useful in the Nutritional Management of Digestive Disease?

Authors:  Paolo Usai-Satta; Francesco Oppia; Mariantonia Lai; Francesco Cabras
Journal:  Nutrients       Date:  2021-03-17       Impact factor: 5.717

Review 7.  Lactose Malabsorption and Presumed Related Disorders: A Review of Current Evidence.

Authors:  Paolo Usai-Satta; Mariantonia Lai; Francesco Oppia
Journal:  Nutrients       Date:  2022-01-28       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.